Systematic Analysis of Covalent and Allosteric Protein Kinase Inhibitors.

X-ray structures allosteric inhibitors binding sites covalent inhibitors potency promiscuity protein kinases warheads

Journal

Molecules (Basel, Switzerland)
ISSN: 1420-3049
Titre abrégé: Molecules
Pays: Switzerland
ID NLM: 100964009

Informations de publication

Date de publication:
01 Aug 2023
Historique:
received: 17 07 2023
revised: 24 07 2023
accepted: 31 07 2023
medline: 14 8 2023
pubmed: 12 8 2023
entrez: 12 8 2023
Statut: epublish

Résumé

In drug discovery, protein kinase inhibitors (PKIs) are intensely investigated as drug candidates in different therapeutic areas. While ATP site-directed, non-covalent PKIs have long been a focal point in protein kinase (PK) drug discovery, in recent years, there has been increasing interest in allosteric PKIs (APKIs), which are expected to have high kinase selectivity. In addition, as compounds acting by covalent mechanisms experience a renaissance in drug discovery, there is also increasing interest in covalent PKIs (CPKIs). There are various reasons for this increasing interest such as the anticipated high potency, prolonged residence times compared to non-competitive PKIs, and other favorable pharmacokinetic properties. Due to the popularity of PKIs for therapeutic intervention, large numbers of PKIs and large volumes of activity data have accumulated in the public domain, providing a basis for large-scale computational analysis. We have systematically searched for CPKIs containing different reactive groups (warheads) and investigated their potency and promiscuity (multi-PK activity) on the basis of carefully curated activity data. For seven different warheads, sufficiently large numbers of CPKIs were available for detailed follow-up analysis. For only three warheads, the median potency of corresponding CPKIs was significantly higher than of non-covalent PKIs. However, for CKPIs with five of seven warheads, there was a significant increase in the median potency of at least 100-fold compared to PKI analogues without warheads. However, in the analysis of multi-PK activity, there was no general increase in the promiscuity of CPKIs compared to non-covalent PKIs. In addition, we have identified 29 new APKIs in X-ray structures of PK-PKI complexes. Among structurally characterized APKIs, 13 covalent APKIs in complexes with five PKs are currently available, enabling structure-based investigation of PK inhibition by covalent-allosteric mechanisms.

Identifiants

pubmed: 37570774
pii: molecules28155805
doi: 10.3390/molecules28155805
pmc: PMC10420927
pii:
doi:

Substances chimiques

Protein Kinase Inhibitors 0
Protein Kinases EC 2.7.-

Types de publication

Systematic Review Journal Article

Langues

eng

Sous-ensembles de citation

IM

Références

J Med Chem. 2019 Nov 14;62(21):9375-9414
pubmed: 31050421
ACS Omega. 2019 Jan 14;4(1):1027-1032
pubmed: 31459378
Nat Rev Endocrinol. 2018 Dec;15(1):21-32
pubmed: 30275460
J Med Chem. 2020 Dec 24;63(24):15494-15507
pubmed: 33226222
Nat Rev Drug Discov. 2021 Jan;20(1):39-63
pubmed: 33077936
Nucleic Acids Res. 2012 Jan;40(Database issue):D1100-7
pubmed: 21948594
Eur J Med Chem. 2021 Apr 15;216:113318
pubmed: 33730624
Cell Chem Biol. 2021 Oct 21;28(10):1433-1445.e3
pubmed: 34077750
Pharmacol Res. 2023 Jan;187:106552
pubmed: 36403719
Nat Rev Drug Discov. 2021 Nov;20(11):839-861
pubmed: 34354255
Nucleic Acids Res. 2007 Jan;35(Database issue):D198-201
pubmed: 17145705
RSC Med Chem. 2020 Jul 2;11(8):876-884
pubmed: 33479682
Science. 2002 Dec 6;298(5600):1912-34
pubmed: 12471243
Nat Rev Drug Discov. 2018 May;17(5):353-377
pubmed: 29545548
Nat Rev Drug Discov. 2021 Jul;20(7):551-569
pubmed: 34002056
Nucleic Acids Res. 2023 Jan 6;51(D1):D523-D531
pubmed: 36408920
J Med Chem. 2022 Jan 27;65(2):922-934
pubmed: 33476146
Angew Chem Int Ed Engl. 2018 Apr 9;57(16):4372-4385
pubmed: 28994500
Nat Rev Cancer. 2010 Feb;10(2):130-7
pubmed: 20094047
Protein Sci. 2020 Jan;29(1):52-65
pubmed: 31531901
Nat Rev Drug Discov. 2022 Dec;21(12):881-898
pubmed: 36008483
J Med Chem. 2023 Jun 8;66(11):7657-7665
pubmed: 37212701
J Med Chem. 2019 Jun 27;62(12):5673-5724
pubmed: 30565923
Medchemcomm. 2016 Apr 1;7(4):576-585
pubmed: 27398190
Angew Chem Int Ed Engl. 2020 Aug 10;59(33):13764-13776
pubmed: 31889388
Crit Rev Biochem Mol Biol. 2014 Mar-Apr;49(2):102-15
pubmed: 24564382
Nat Chem Biol. 2015 Nov;11(11):818-21
pubmed: 26485069
Chem Soc Rev. 2020 May 7;49(9):2617-2687
pubmed: 32227030

Auteurs

Elena Xerxa (E)

LIMES Program Unit Chemical Biology and Medicinal Chemistry, Department of Life Science Informatics, B-IT, Rheinische Friedrich-Wilhelms-Universität, Friedrich-Hirzebruch-Allee 5/6, D-53115 Bonn, Germany.

Oliver Laufkötter (O)

LIMES Program Unit Chemical Biology and Medicinal Chemistry, Department of Life Science Informatics, B-IT, Rheinische Friedrich-Wilhelms-Universität, Friedrich-Hirzebruch-Allee 5/6, D-53115 Bonn, Germany.

Jürgen Bajorath (J)

LIMES Program Unit Chemical Biology and Medicinal Chemistry, Department of Life Science Informatics, B-IT, Rheinische Friedrich-Wilhelms-Universität, Friedrich-Hirzebruch-Allee 5/6, D-53115 Bonn, Germany.

Articles similaires

Animals TOR Serine-Threonine Kinases Colorectal Neoplasms Colitis Mice
Humans Melanoma Skin Neoplasms Antineoplastic Combined Chemotherapy Protocols Randomized Controlled Trials as Topic
Humans Chondrocytes Osteoarthritis Matrix Metalloproteinase 13 Drug Discovery
Humans Formins Phosphorylation Exosomes Jurkat Cells

Classifications MeSH